Form 4: Elanco Animal Health CEO Jeffrey Simmons Reports Acquisition of Deferred Stock Units

Elanco Animal Health's CEO, Jeffrey N. Simmons, reported the acquisition of deferred stock units convertible to common stock, according to a Form 4 filing with the SEC.

Summary

• On January 10, 2025, Jeffrey N. Simmons, the President, CEO, and Director of Elanco Animal Health Inc., acquired 242.2782 deferred stock units.
• These deferred stock units represent the right to receive one share of Elanco common stock or the cash equivalent.
• The price of each derivative security is $11.43.
• Following the transaction, Simmons directly owns 5,234.812 derivative securities.
• The deferred stock units will settle in cash or shares of Elanco common stock following termination of employment or during a specified future year, as per the Executive Deferral and Stock Match Plan.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a routine disclosure of executive compensation. The acquisition of stock units by the CEO is generally a positive sign, but it's a standard practice.

Positives

• The acquisition of deferred stock units by the CEO could be seen as a positive sign, indicating confidence in the company's future performance.

Future Outlook

The deferred stock units will settle in cash or shares of Company common stock following termination of employment or during a specified future year in accordance with Executive Deferral and Stock Match Plan.

Industry Context

Executive compensation in the animal health industry often includes stock-based awards to align management's interests with those of shareholders. This Form 4 filing reflects such a practice at Elanco Animal Health.

Stakeholder Impact

• The acquisition of deferred stock units by the CEO could positively influence shareholder sentiment, reflecting confidence in the company's leadership and future prospects.

Key Dates